Table Info

Table 1.

Long COVID clinical trials/studies involving CBMPs (also including CBD/hemp-based supplements)

NCT number	Title	Country	Status	Study design	Participants	Condition	Intervention	Publications
NCT04997395	Feasibility of cannabidiol for the treatment of Long COVID	UK	Active, not recruiting	Phase 2, open label	Adults over 18. N = 30	Long COVID	MediCabilis 5% CBD Oil (UK trade name: MediCabilis™ Cannabis sativa 50). Daily dose up to 150 mg CBD, 6 mg THC for 5 months	Not published
NCT05467904	Double-blind randomized placebo-controlled trial of a proprietary full hemp flower formulation for Long COVID	USA	Not yet recruiting	Placebo controlled. Phase not stated	Adults 18–65. N = 111	Post-acute COVID-19 syndrome (Long COVID)	Full hemp flower formulation (Xltran Plus™ and Xltran™) for 28 days	Not published
NCT04828668	Study to evaluate benefits & safety of Endourage Formula C™ oral drops in people with post-acute COVID-19 syndrome	USA	Completed	Placebo controlled. Phase not stated	Adults 18–75. N = 60	Post-acute COVID-19 syndrome (Long COVID)	Formula C™ sublingual drops for 28 days (Extracted from hemp flower)	Published [114]

NCT number

Title

Country

Status

Study design

Participants

Condition

Intervention

Publications

NCT04997395

Feasibility of cannabidiol for the treatment of Long COVID

Active, not recruiting

Phase 2, open label

Adults over 18. N = 30

Long COVID

MediCabilis 5% CBD Oil

(UK trade name: MediCabilis™ Cannabis sativa 50). Daily dose up to 150 mg CBD, 6 mg THC for 5 months

Not published

NCT05467904

Double-blind randomized placebo-controlled trial of a proprietary full hemp flower formulation for Long COVID

USA

Not yet recruiting

Placebo controlled. Phase not stated

Adults 18–65. N = 111

Post-acute COVID-19 syndrome (Long COVID)

Full hemp flower formulation (Xltran Plus™ and Xltran™) for 28 days

Not published

NCT04828668

Study to evaluate benefits & safety of Endourage Formula C™ oral drops in people with post-acute COVID-19 syndrome

USA

Completed

Placebo controlled. Phase not stated

Adults 18–75. N = 60

Post-acute COVID-19 syndrome (Long COVID)

Formula C™ sublingual drops for 28 days (Extracted from hemp flower)

Published [114]

USA: United States of America; N: refers to the number of study participants

Declarations

Author contributions

HT, AKS, and EI: Conceptualization, Writing—original draft, Writing—review & editing. AH and ML: Conceptualization, Writing—review & editing. DJN: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

Author DJN is the Chair of the charity Drug Science. Author ML is the Chief Research Officer of Drug Science. Author AKS is the Head of Research of Drug Science and scientific advisor to the Primary Care Cannabis Network, and an executive member of the Cannabis Industry Council, both unpaid roles. Author HT is a Senior Research Officer and Study Coordinator of the medical cannabis and Long COVID clinical trial at Drug Science. Author EI is an expert member of the Drug Science Medical Cannabis Working and Principial Investigator of medical cannabis and Long COVID clinical trial at Drug Science. Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, which is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class. All Drug Science committee members, including the Chair, are unpaid by Drug Science for their effort and commitment to this organization. None of the authors would benefit from the wider prescription of medical cannabis in any form. AH was Chief Scientific Officer at Bod Australia Limited which is the sponsor of a medical cannabis and Long COVID clinical trial at Drug Science.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

WHO coronavirus (COVID-19) dashboard 2022 [Internet]. World Health Organization; c2023 [cited 2022 Nov 24]. Available from: https://covid19.who.int

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–46. [DOI] [PubMed] [PMC]

Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52:575–81. [DOI] [PubMed] [PMC]

Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or Long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593–607. [DOI] [PubMed] [PMC]

Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55–70. [DOI] [PubMed] [PMC]

Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657–66. [DOI] [PubMed] [PMC]

Rehabilitation, recognition and research needed for people living with long COVID: new WHO/Europe factsheet [Internet]. World Health Organization; c2023 [cited 2022 Dec 1]. Available from: https://who.canto.global/pdfviewer/viewer/viewer.html?v=JJA37JMFLT&portalType=v%2FJJA37JMFLT&column=document&id=69darire811l718b3aq106mk73&suffix=pdf&print=1

Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938. [DOI] [PubMed] [PMC]

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. [DOI] [PubMed] [PMC]

10.

O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. [DOI] [PubMed] [PMC]

11.

Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. [DOI] [PubMed] [PMC]

12.

Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427. [DOI] [PubMed] [PMC]

13.

Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022;101:48–52. [DOI] [PubMed] [PMC]

14.

Ledford H. How common is long COVID? why studies give different answers. Nature. 2022;606:852–3. [DOI] [PubMed]

15.

Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. [DOI] [PubMed] [PMC]

16.

Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. [DOI] [PubMed] [PMC]

17.

Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. [DOI] [PubMed] [PMC]

18.

Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. [DOI] [PubMed] [PMC]

19.

Maltezou HC, Pavli A, Tsakris A. Post-COVID syndrome: an insight on its pathogenesis. Vaccines (Basel). 2021;9:497. [DOI] [PubMed] [PMC]

20.

Beyerstedt S, Casaro EB, Rangel É. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40:905–19. [DOI] [PubMed] [PMC]

21.

Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422. [DOI] [PubMed] [PMC]

22.

Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: a review. J Infect Public Health. 2020;13:1619–29.

23.

Ambrosino P, Sanduzzi Zamparelli S, Mosella M, Formisano R, Molino A, Spedicato GA, et al. Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions. Ann Med. 2022;54:3234–49. [DOI] [PubMed] [PMC]

24.

Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583–90. [DOI] [PubMed] [PMC]

25.

Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023;44:695–709. [DOI] [PubMed] [PMC]

26.

Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022;20:138. [DOI] [PubMed] [PMC]

27.

Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, Kümpers P, et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis. 2023;26:53–61. [DOI] [PubMed] [PMC]

28.

Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758. [DOI] [PubMed] [PMC]

29.

Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–95.e20. [DOI] [PubMed] [PMC]

30.

Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid-an update for primary care. BMJ. 2022;378:e072117. [DOI] [PubMed]

31.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019;365:l1141. [DOI] [PubMed] [PMC]

32.

Gonçalves J, Rosado T, Soares S, Simão AY, Caramelo D, Luís Â, et al. Cannabis and its secondary metabolites: their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines (Basel). 2019;6:31. [DOI] [PubMed] [PMC]

33.

Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833. [DOI] [PubMed] [PMC]

34.

Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep. 1999;16:131–43. [DOI] [PubMed]

35.

Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353:23–31. [DOI] [PubMed]

36.

Schlag AK, O’Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021;191:108586. [DOI] [PubMed]

37.

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344–64. [DOI] [PubMed] [PMC]

38.

van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, et al. Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. J Nat Prod. 2022;85:176–84. [DOI] [PubMed]

39.

Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2018;9:1969. [DOI] [PubMed] [PMC]

40.

Olsson F, Erridge S, Tait J, Holvey C, Coomber R, Beri S, et al. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Rev Clin Pharmacol. 2023;16:257–66. [DOI] [PubMed]

41.

Schlag AK, Lynskey M, Fayaz A, Athanasiou-Fragkouli A, Brandner B, Haja B, et al. Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from Project Twenty 21. Front Pain Res (Lausanne). 2022;3:891498. [DOI] [PubMed] [PMC]

42.

Medical Cannabis Clinicians Society. Recommendations and guidance on medical cannabis under prescription. 2nd ed. The Society; 2020 Jan.

43.

Schlag AK, Zafar RR, Lynskey MT, Athanasiou-Fragkouli A, Phillips LD, Nutt DJ. The value of real world evidence: the case of medical cannabis. Front Psychiatry. 2022;13:1027159. [DOI] [PubMed] [PMC]

44.

Oregon Health Authority. Oregon medical marijuana program statistics. Portland: The Authority; 2022 Oct.

45.

Colorado department of public health and environment [Internet]. Colorado: Medical marijuana registry statistics; c2023 [cited 2022 Nov 24]. Available from: https://cdphe.colorado.gov/medical-marijuana-registry-data

46.

Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4:bjgpopen20X101010. [DOI] [PubMed] [PMC]

47.

Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019;12:1577–604. [DOI] [PubMed] [PMC]

48.

Wright M, Di Ciano P, Brands B. Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5:191–6. [DOI] [PubMed] [PMC]

49.

Nutt DJ, Phillips LD, Barnes MP, Brander B, Curran HV, Fayaz A, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis Cannabinoid Res. 2022;7:482–500. [DOI] [PubMed] [PMC]

50.

Moreno-Sanz G, Madiedo A, Lynskey M, Brown MRD. “Flower power”: controlled inhalation of THC-predominant cannabis flos improves health-related quality of life and symptoms of chronic pain and anxiety in eligible UK patients. Biomedicines. 2022;10:2576. [DOI] [PubMed] [PMC]

51.

Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. Patient-reported symptom relief following medical cannabis consumption. Front Pharmacol. 2018;9:916. [DOI] [PubMed] [PMC]

52.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456–73. [DOI] [PubMed]

53.

Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10:1353–68. [DOI] [PubMed]

54.

Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–96. [PubMed]

55.

Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21:479–506. [DOI] [PubMed] [PMC]

56.

Lynskey MT, Schlag AK, Athanasiou-Fragkouli A, Badcock D, Nutt DJ. Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real world evidence from Project Twenty21. Drug Sci Policy Law. 2023;9. [DOI]

57.

Gruber SA, Smith RT, Dahlgren MK, Lambros AM, Sagar KA. No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms. Exp Clin Psychopharmacol. 2021;29:147–56. [DOI] [PubMed]

58.

Bar-Lev Schleider L, Mechoulam R, Sikorin I, Naftali T, Novack V. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front Med (Lausanne). 2022;9:827849. [DOI] [PubMed] [PMC]

59.

Harris M, Erridge S, Ergisi M, Nimalan D, Kawka M, Salazar O, et al. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Rev Clin Pharmacol. 2022;15:473–85. [DOI] [PubMed]

60.

Meng H, Page MG, Ajrawat P, Deshpande A, Samman B, Dominicis M, et al. Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Can J Anaesth. 2021;68:633–44. [DOI] [PubMed]

61.

Vickery AW, Roth S, Ernenwein T, Kennedy J, Washer P. A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLoS One. 2022;17:e0272241. [DOI] [PubMed] [PMC]

62.

Safakish R, Ko G, Salimpour V, Hendin B, Sohanpal I, Loheswaran G, et al. Medical cannabis for the management of pain and quality of life in chronic pain patients: a prospective observational study. Pain Med. 2020;21:3073–86. [DOI] [PubMed]

63.

Sherpa ML, Shrestha N, Ojinna BT, Ravi N, Shantha Kumar V, Choday S, et al. Efficacy and safety of medical marijuana in migraine headache: a systematic review. Cureus. 2022;14:e32622. [DOI] [PubMed] [PMC]

64.

Okusanya BO, Lott BE, Ehiri J, McClelland J, Rosales C. Medical cannabis for the treatment of migraine in adults: a review of the evidence. Front Neurol. 2022;13:871187. [DOI] [PubMed] [PMC]

65.

Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023;28:564–78. [DOI] [PubMed] [PMC]

66.

Frere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, Golynker I, et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med. 2022;14:eabq3059. [DOI] [PubMed] [PMC]

67.

Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12:825–36. [DOI] [PubMed] [PMC]

68.

Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, et al. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. J Psychopharmacol. 2022;36:1299–314. [DOI] [PubMed] [PMC]

69.

Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466. [DOI] [PubMed] [PMC]

70.

Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond). 2022;2:139. [DOI] [PubMed] [PMC]

71.

Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81:331–42. [DOI] [PubMed]

72.

O’Sullivan SE, Stevenson CW, Laviolette SR. Could cannabidiol be a treatment for coronavirus disease-19-related anxiety disorders? Cannabis Cannabinoid Res. 2021;6:7–18. [DOI] [PubMed] [PMC]

73.

Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, et al. An updated analysis of clinical outcome measures across patients from the UK Medical Cannabis Registry. Cannabis Cannabinoid Res. 2023;8:557–66. [DOI] [PubMed]

74.

Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6:995–1010. [DOI] [PubMed] [PMC]

75.

Gruber SA, Sagar KA, Dahlgren MK, Gonenc A, Smith RT, Lambros AM, et al. The grass might be greener: medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front Pharmacol. 2017;8:983. [DOI] [PubMed] [PMC]

76.

Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021;12:729800. [DOI] [PubMed] [PMC]

77.

Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694. [DOI] [PubMed] [PMC]

78.

AminiLari M, Wang L, Neumark S, Adli T, Couban RJ, Giangregorio A, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022;45:zsab234. [DOI] [PubMed]

79.

Batalla A, Bos J, Postma A, Bossong MG. The impact of cannabidiol on human brain function: a systematic review. Front Pharmacol. 2020;11:618184. [DOI] [PubMed] [PMC]

80.

Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310–24. [DOI] [PubMed]

81.

Wieghorst A, Roessler KK, Hendricks O, Andersen TE. The effect of medical cannabis on cognitive functions: a systematic review. Syst Rev. 2022;11:210. [DOI] [PubMed] [PMC]

82.

Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795–808. [DOI] [PubMed]

83.

Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsychol Soc. 2021;27:648–60. [DOI] [PubMed]

84.

Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D, Belausov E, et al. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 2021;11:1462. [DOI] [PubMed] [PMC]

85.

Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9:21. [DOI] [PubMed] [PMC]

86.

Robaina Cabrera CL, Keir-Rudman S, Horniman N, Clarkson N, Page C. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulm Pharmacol Ther. 2021;69:102047. [DOI] [PubMed]

87.

Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11:714. [DOI] [PubMed] [PMC]

88.

Costiniuk CT, Jenabian MA. Acute inflammation and pathogenesis of SARS-CoV-2 infection: cannabidiol as a potential anti-inflammatory treatment? Cytokine Growth Factor Rev. 2020;53:63–5. [DOI] [PubMed] [PMC]

89.

Nagarkatti P, Miranda K, Nagarkatti M. Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with coronavirus disease-2019. Front Pharmacol. 2020;11:589438. [DOI] [PubMed] [PMC]

90.

Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I, et al. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020;12:22425–44. [DOI] [PubMed] [PMC]

91.

Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194–202. [DOI] [PubMed] [PMC]

92.

Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG, Hallak JE, et al. Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. Eur J Pharmacol. 2019;843:251–9. [DOI] [PubMed]

93.

George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–15. [DOI] [PubMed] [PMC]

94.

Sarkar I, Sen G, Bhattacharya M, Bhattacharyya S, Sen A. In silico inquest reveals the efficacy of cannabis in the treatment of post-Covid-19 related neurodegeneration. J Biomol Struct Dyn. 2022;40:8030–9. [DOI] [PubMed]

95.

Mabou Tagne A, Pacchetti B, Sodergren M, Cosentino M, Marino F. Cannabidiol for viral diseases: hype or hope? Cannabis Cannabinoid Res. 2020;5:121–31. [DOI] [PubMed] [PMC]

96.

Janecki M, Graczyk M, Lewandowska AA, Pawlak Ł. Anti-inflammatory and antiviral effects of cannabinoids in inhibiting and preventing SARS-CoV-2 infection. Int J Mol Sci. 2022;23:4170. [DOI] [PubMed] [PMC]

97.

Medveczky MM, Sherwood TA, Klein TW, Friedman H, Medveczky PG. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med. 2004;2:34. [DOI] [PubMed] [PMC]

98.

Chadda KR, Blakey EE, Huang CL, Jeevaratnam K. Long COVID-19 and postural orthostatic tachycardia syndrome- is dysautonomia to be blamed? Front Cardiovasc Med. 2022;9:860198. [DOI] [PubMed] [PMC]

99.

Long COVID community rehabilitation booklet [Internet]. Leeds Community Healthcare NHS Trust; c2023 [cited 2022 November 24]. Available from: https://www.leedscommunityhealthcare.nhs.uk/our-services-a-z/long-covid-community-rehabilitation/

100.

Heart rate, blood pressure and temperature: Dysautonomia [Internet]. Somerset NHS Foundation Trust; c2023 [cited 2022 Nov 22]. Available from: https://www.somersetft.nhs.uk/somersetlongcovid/somerset-post-covid-assessment-service/what-is-post-covid-syndrome-and-how-does-it-affect-people/heart-rate/

101.

Larsen NW, Stiles LE, Shaik R, Schneider L, Muppidi S, Tsui CT, et al. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. Front Neurol. 2022;13:1012668. [DOI] [PubMed] [PMC]

102.

Eldokla AM, Mohamed-Hussein AA, Fouad AM, Abdelnaser MG, Ali ST, Makhlouf NA, et al. Prevalence and patterns of symptoms of dysautonomia in patients with long-COVID syndrome: a cross-sectional study. Ann Clin Transl Neurol. 2022;9:778–85. [DOI] [PubMed] [PMC]

103.

Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021;21:e63–7. [DOI] [PubMed] [PMC]

104.

Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne). 2014;5:205. [DOI] [PubMed] [PMC]

105.

Haensch CA, Jörg J. Autonomic dysfunction in multiple sclerosis. J Neurol. 2006;253 Suppl 1:i3–9. [DOI] [PubMed]

106.

Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther. 2007;9:216. [DOI] [PubMed] [PMC]

107.

Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014;4:805–26. [DOI] [PubMed] [PMC]

108.

Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis ‒ the Canadian perspective. J Pain Res. 2016;9:735–44. [DOI] [PubMed] [PMC]

109.

Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021;11:14042. [DOI] [PubMed] [PMC]

110.

Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. [DOI] [PubMed] [PMC]

111.

Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15:151–66. [DOI] [PubMed]

112.

Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75:313–22. [DOI] [PubMed] [PMC]

113.

Kicman A, Toczek M. The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease. Int J Mol Sci. 2020;21:6740. [DOI] [PubMed] [PMC]

114.

Young TP, Erickson JS, Hattan SL, Guzy S, Hershkowitz F, Steward MD. A single-blind, randomized, placebo controlled study to evaluate the benefits and safety of endourage targeted wellness Formula C sublingual +drops in people with post-acute coronavirus disease 2019 syndrome. Cannabis Cannabinoid Res. 2022;[Epub ahead of print]. [DOI] [PubMed]